Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H13N2O8.3Na |
| Molecular Weight | 370.1988 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[Na+].CC(=O)N[C@@H](CC([O-])=O)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O
InChI
InChIKey=WGWMBRZJCFSSLL-UEEQWHBPSA-K
InChI=1S/C11H16N2O8.3Na/c1-5(14)12-7(4-9(17)18)10(19)13-6(11(20)21)2-3-8(15)16;;;/h6-7H,2-4H2,1H3,(H,12,14)(H,13,19)(H,15,16)(H,17,18)(H,20,21);;;/q;3*+1/p-3/t6-,7-;;;/m0.../s1
PubMed
| Title | Date | PubMed |
|---|---|---|
| [N acetyl-aspartyl glutamic acid (NAAGA) inhibits the adhesion of leukocytes to activated endothelial cells and down-modulates the cytokine-induced expression of adhesion molecules]. | 2002 Dec |
|
| Brain metabolite composition during early human brain development as measured by quantitative in vivo 1H magnetic resonance spectroscopy. | 2002 Dec |
|
| Glutamine uptake and metabolism to N-acetylaspartylglutamate (NAAG) by crayfish axons and glia. | 2002 Oct |
|
| Morphology and ultrastructure of rat hippocampal formation after i.c.v. administration of N-acetyl-L-aspartyl-L-glutamate. | 2003 |
|
| Reductions in N-acetylaspartylglutamate and the 67 kDa form of glutamic acid decarboxylase immunoreactivities in the visual system of albino and pigmented rats after optic nerve transections. | 2003 Apr 7 |
|
| Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. | 2003 Dec 15 |
|
| Cerebral proton magnetic resonance spectroscopy of a patient with giant axonal neuropathy. | 2003 Jan |
|
| N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. | 2003 Jun 15 |
|
| Characterisation of the 1H and 13C NMR spectra of N-acetylaspartylglutamate and its detection in urine from patients with Canavan disease. | 2003 Mar 10 |
|
| Metabotropic glutamate receptor regulation of neuronal cell death. | 2003 Nov |
|
| N-acetylaspartylglutamate and beta-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures. | 2003 Nov 21 |
|
| Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. | 2003 Oct 1 |
|
| Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. | 2004 Apr |
|
| Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia. | 2004 Aug |
|
| Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain. | 2004 Aug 6 |
|
| High-field localized 1H NMR spectroscopy in the anesthetized and in the awake monkey. | 2004 Dec |
|
| GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. | 2004 Jan |
|
| Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. | 2004 Jul |
|
| Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. | 2004 Mar 25 |
|
| NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. | 2004 May |
|
| The cloning and characterization of a second brain enzyme with NAAG peptidase activity. | 2004 May |
|
| Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF. | 2004 May 11 |
|
| Serotonin1B receptors: from protein to physiological function and behavior. | 2004 Oct |
|
| Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. | 2004 Sep |
|
| NAAG peptidase inhibitors and their potential for diagnosis and therapy. | 2005 Dec |
|
| Strategies to increase central N-acetyl aspartylglutamate: a potential treatment for schizophrenia and bipolar disorders. | 2005 Jul 15 |
|
| In vitro 1H NMR spectroscopy shows an increase in N-acetylaspartylglutamate and glutamine content in the hippocampus of amygdaloid-kindled rats. | 2005 Mar |
|
| Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. | 2005 Mar 1 |
|
| Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. | 2005 Mar 16 |
|
| Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopy. | 2005 May |
|
| Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors. | 2005 May |
|
| Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. | 2005 Nov |
|
| Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. | 2005 Sep |
|
| The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. | 2005 Sep |
|
| The metabotropic glutamate receptor mGluR3 is critically required for hippocampal long-term depression and modulates long-term potentiation in the dentate gyrus of freely moving rats. | 2005 Sep |
|
| Synthesis of N-acetylaspartyl-glutamate (NAAG) and N-acetylaspartate (NAA) in axons and glia of the crayfish medial giant nerve fiber. | 2006 |
|
| Functions of N-acetylaspartate and N-acetylaspartylglutamate in brain: evidence of a role in maintenance of higher brain integrative activities of information processing and cognition. | 2006 |
|
| Expression of N-acetylaspartate and N-acetylaspartylglutamate in the nervous system. | 2006 |
|
| A brief overview of N-acetylaspartate and N-acetylaspartylglutamate. | 2006 |
|
| NAAG peptidase as a therapeutic target: Potential for regulating the link between glucose metabolism and cognition. | 2006 Apr |
|
| ProFit: two-dimensional prior-knowledge fitting of J-resolved spectra. | 2006 Apr |
|
| Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. | 2006 Dec |
|
| Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. | 2006 Feb |
|
| Neurotransmitters of the suprachiasmatic nuclei. | 2006 Feb 16 |
|
| Identifying the affected hemisphere by (1)H-MR spectroscopy in patients with temporal lobe epilepsy and no pathological findings in high resolution MRI. | 2006 May |
|
| NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. | 2006 May |
|
| Neonatal administration of N-acetyl-L-aspartyl-L-glutamate induces early neurodegeneration in hippocampus and alters behaviour in young adult rats. | 2006 May-Jun |
|
| Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. | 2006 Sep |
|
| Metabolic analysis of mouse brains that have compromised iron storage. | 2006 Sep |
|
| [Alteration of the antinociceptive systems in chronic daily headaches]. | 2006 Sep 1-15 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
57096-28-3
Created by
admin on Sat Dec 16 10:48:15 GMT 2023 , Edited by admin on Sat Dec 16 10:48:15 GMT 2023
|
PRIMARY | |||
|
SUB30553
Created by
admin on Sat Dec 16 10:48:15 GMT 2023 , Edited by admin on Sat Dec 16 10:48:15 GMT 2023
|
PRIMARY | |||
|
100000115278
Created by
admin on Sat Dec 16 10:48:15 GMT 2023 , Edited by admin on Sat Dec 16 10:48:15 GMT 2023
|
PRIMARY | |||
|
Z7Y1U20IBU
Created by
admin on Sat Dec 16 10:48:15 GMT 2023 , Edited by admin on Sat Dec 16 10:48:15 GMT 2023
|
PRIMARY | |||
|
90479713
Created by
admin on Sat Dec 16 10:48:15 GMT 2023 , Edited by admin on Sat Dec 16 10:48:15 GMT 2023
|
PRIMARY | |||
|
133585-88-3
Created by
admin on Sat Dec 16 10:48:15 GMT 2023 , Edited by admin on Sat Dec 16 10:48:15 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY |
ACTIVE MOIETY
SUBSTANCE RECORD
